Clinical Trial Update: Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension [Phase 2]

View source ↗

Summary

An open-label Phase 2 extension study of empagliflozin (BI 10773) in adults with type 2 diabetes has completed enrollment, and results from the extension trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2014-06-16